Preface ix Foreword xi 1 Fundamental concepts 1 1.1 What is a clinical trial? 1 1.2 Early trials 2 1.3 Why clinical trials are needed 3 1.4 Alternatives to clinical trials 3 1.5 Types of clinical trials 5 1.6 Key design features 7 1.7 Summary points 13 2 Types of outcome measures and understanding them 15 2.
1 Clinical trial outcome measures (endpoints) 15 2.2 ''True'' versus surrogate outcome measures 16 2.3 Types of outcomes 18 2.4 Counting people 18 2.5 Taking measurements on people 19 2.6 Time-to-event measures 21 2.7 Patient-reported outcome measures (PROMs) 25 2.8 Summary points 27 3 Phase I trials 29 3.
1 Trial objectives 29 3.2 Types of participants 30 3.3 Outcome measures 30 3.4 Designs 32 3.5 Conducting the trial 37 3.6 Statistical analysis and reporting the trial results 37 3.7 Summary points 39 4 Phase II trials 41 4.1 Trial objectives 41 4.
2 Designs 41 4.3 Outcome measures 48 4.4 Estimating study size 48 4.5 Stopping early for toxicity 50 4.6 Statistical analyses 51 4.7 Interpreting phase II studies 55 4.8 Summary points 56 5 Phase III trials: design 59 5.1 Trial objectives 59 5.
2 Designs 59 5.3 Inclusion and exclusion criteria 62 5.4 Experimental/investigational treatment group 64 5.5 Control (comparator) group 64 5.6 Randomisation and allocating participants 65 5.7 Blinding (placebo) 66 5.8 Outcome measures 66 5.9 Participant follow-up 68 5.
10 Estimating study size 69 5.11 Non-inferiority and equivalence 72 5.12 Multiplicity: multiple treatment arms or multiple outcome measures 74 5.13 Participants who switch trial interventions (crossover) 75 5.14 Summary points 76 6 Phase III trials - fundamental aspects of analysis and interpretation 79 6.1 Efficacy 79 6.2 Safety toxicity and adverse events 96 6.3 Adherence (compliance) 98 6.
4 Healthrelated quality of life (QoL) 99 6.5 Intentiontotreat and perprotocol analyses 102 6.6 Summary points 103 7 Randomised trials - additional aspects of analysis and interpretation 107 7.1 Non-inferiority and equivalence trials 107 7.2 Composite outcome measures 110 7.3 Subgroup (subset) analyses 111 7.4 Crossover trials 115 7.5 Factorial trials 115 7.
6 Cluster randomised trial 117 7.7 Repeated measures 117 7.8 Multiple endpoints 117 7.9 Dealing with missing outcome data 119 7.10 Translational research 120 8 Commercial trials of medicinal products; other types of interventions; health economic analysis 127 8.1 Commercial trials of medicines (drugs) 127 8.2 Other types of interventions 135 Surgical techniques 137 Radiotherapy and radioactive substances 139 Behavioural/lifestyle interventions 139 Medical devices 141 Cell and gene therapy 142 8.3 Health economic analyses 144 9 Systematic reviews and meta-analyses; and real-world evidence 147 9.
1 Systematic reviews of randomised controlled trials (direct comparisons) 147 9.2 Meta-analyses based on indirect comparisons 154 9.3 Real-world evidence and real-world data 159 9.4 Summary points 166 10 Conducting and reporting trials 169 10.1 Working group and key roles 169 10.2 Estimate and secure funding 170 10.3 Patient and Public Involvement and Engagement (PPIE) 171 10.4 Essential trial documents 171 Trial protocol 171 Participant/Patient Information Sheet (PIS) and Consent Form 172 Case report forms (CRFs) 175 Electronic database (randomisation system) 176 Standard operating procedures (SOPs) 176 Investigator''s Brochure (IB) 177 Trial Master File (TMF) 177 10.
5 Ethics and regulatory approvals 177 10.6 Trial set up 179 Register the trial 179 Contracts and agreements 179 Assess site feasibility 181 Site initiation and activation 181 Handling and distribution of trial drugs 181 Handling and shipping of biospecimens or imaging scans 182 10.7 Conducting the trial 182 10.8 Monitoring the trial and suspension/early stopping 184 Safety monitoring and reporting 185 10.9 End of trial 188 10.10 Reporting and publishing trials 190 10.11 Regulations and guidance associated with conducting trials 191 10.12 Why trials ''fail'' 194 Clinical trial critical appraisal checklist 199 Glossary of abbreviations used in clinical trials 201 Further reading 205 Index 207.